Jefferies Group set a $22.00 target price on Evolent Health (NYSE:EVH) in a report released on Tuesday morning. The firm currently has a buy rating on the technology company’s stock.

Several other analysts also recently commented on EVH. Robert W. Baird restated a buy rating and set a $25.00 price objective on shares of Evolent Health in a research report on Wednesday, November 1st. Citigroup began coverage on shares of Evolent Health in a research report on Thursday, January 4th. They set a buy rating on the stock. Leerink Swann set a $25.00 price objective on shares of Evolent Health and gave the company a buy rating in a research report on Saturday, November 18th. Cantor Fitzgerald restated a buy rating and set a $30.00 price objective on shares of Evolent Health in a research report on Thursday, November 2nd. Finally, Goldman Sachs Group downgraded shares of Evolent Health from a conviction-buy rating to a buy rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company’s stock. Evolent Health has an average rating of Buy and an average target price of $27.40.

Shares of Evolent Health (NYSE EVH) opened at $13.65 on Tuesday. The company has a market cap of $1,040.00 and a price-to-earnings ratio of -11.97. Evolent Health has a 52-week low of $10.30 and a 52-week high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lombard Odier Asset Management USA Corp grew its stake in Evolent Health by 26.5% during the fourth quarter. Lombard Odier Asset Management USA Corp now owns 379,441 shares of the technology company’s stock valued at $4,667,000 after acquiring an additional 79,441 shares in the last quarter. Geode Capital Management LLC grew its stake in Evolent Health by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 503,415 shares of the technology company’s stock valued at $6,192,000 after acquiring an additional 18,461 shares in the last quarter. Jackson Square Partners LLC purchased a new position in Evolent Health during the fourth quarter valued at $534,000. Cortina Asset Management LLC grew its stake in Evolent Health by 43.4% during the fourth quarter. Cortina Asset Management LLC now owns 413,406 shares of the technology company’s stock valued at $5,085,000 after acquiring an additional 125,053 shares in the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new position in Evolent Health during the fourth quarter valued at $11,630,000. 95.44% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/14/jefferies-group-reiterates-22-00-price-target-for-evolent-health-evh.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.